YOLFTbeta
Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc

ARCT · NASDAQ · Healthcare / Biotechnology

8.36USD-0.08 (-0.95%)

Price History

Full chart

Market Stats

Previous Close8.44
Open8.43
Day Range8.12 – 8.68
52-Week Range5.50 – 24.17
Volume377.11K
Market Cap401.33M
P/E (TTM)0.00
Forward P/E2.48
EPS-3.33
Dividend Yield0.00%
Beta2.48
50-Day Avg10.86
200-Day Avg8.31

About

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Joseph E. Payne M.Sc.
  • Employees106
  • Headquarters10285 Science Center Drive, San Diego, CA, United States, 92121, USA
  • Websitehttps://arcturusrx.com

Leadership

  • Mr. Joseph E. Payne M.Sc.Founder, President, CEO & Director · b. 1972
  • Dr. Padmanabh Chivukula Ph.D.Founder, Chief Scientific Officer, COO & Secretary · b. 1979
  • Mr. Joseph RobertsPrincipal Accounting Officer & Controller · b. 1983
  • Mr. Lance KurataChief Legal Officer
  • Mr. Dennis M. MulroyChief Financial Officer · b. 1955
  • Ms. Neda SafarzadehVice President and Head of IR/PR & Marketing
  • Ms. Natasha O. BowmanChief Human Resources Officer
  • Mr. Kevin T. SkolChief Business Officer
  • Dr. Igor Smolenov M.D., Ph.D.Chief Development Officer
  • Dr. Ye ZhangChief Regulatory & Quality Assurance Officer

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--006.14M20.38M13.00M15.75M20.79M9.54M12.36M205.75M157.75M138.39M67.22M
Growth (%)-----+232.06%-36.23%+21.20%+31.97%-54.12%+29.56%+1564.82%-23.33%-12.27%-51.43%
Cost of Revenue--0051.00K294.00K410.00K16.98M32.44M55.95M173.76M143.05M2.96M3.54M3.02M
Gross Profit--006.09M20.09M12.59M-1.23M20.79M-46.41M12.36M205.75M157.75M138.39M64.20M
Gross Margin----99.17%98.56%96.85%-7.80%100.00%-486.50%100.00%100.00%100.00%100.00%95.50%
Operating Expense--10.29M33.08M25.79M45.26M23.08M20.58M46.30M25.12M215.21M193.58M235.95M234.06M139.15M
Operating Income-3.91M-1.50M-10.29M-33.08M-19.70M-25.17M-10.49M-21.81M-25.51M-71.52M-202.85M12.18M-78.20M-95.67M-74.95M
Operating Margin-----320.92%-123.48%-80.72%-138.46%-122.72%-749.81%-1641.33%5.92%-49.58%-69.13%-111.51%
EBITDA-3.92M-1.51M-10.28M-32.81M-1.72M-947.00K-10.34M-20.71M-24.45M-70.64M-199.81M15.17M-24.16M-77.40M-62.76M
EBITDA Margin-----28.02%-4.65%-79.56%-131.50%-117.62%-740.56%-1616.69%7.37%-15.32%-55.93%-93.36%
Net Income-3.93M-1.58M-10.55M-32.83M-19.45M-24.60M-10.90M-21.79M-25.99M-72.15M-203.67M9.35M-29.73M-80.94M-65.78M
Net Income Margin-----316.86%-120.71%-83.87%-138.29%-125.02%-756.35%-1647.98%4.54%-18.84%-58.49%-97.86%
R&D1.82M818.00K7.07M25.11M13.46M18.39M15.92M16.98M33.64M57.85M173.76M147.75M192.13M195.16M112.21M
R&D as % of Total Revenue----219.31%90.23%122.46%107.80%161.82%606.42%1405.94%71.81%121.80%141.02%166.93%
Interest Expense44.00K80.00K197.00K2.00K251.00K295.00K150.00K186.00K854.00K831.00K2.67M3.00M767.00K09.00K
Interest Expense % of Total Revenue----4.09%1.45%1.15%1.18%4.11%8.71%21.64%1.46%0.49%0.00%0.01%

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.20M201.00K50.32M22.32M71.68M51.57M52.02M44.20M82.14M476.46M392.81M450.39M429.40M344.07M271.15M
Total Liabilities219.00K768.00K1.64M2.38M2.35M4.34M18.23M30.56M56.35M79.90M164.60M180.07M150.89M103.09M57.16M
Total Equity985.00K-567.00K48.69M19.94M69.33M47.23M33.79M13.64M25.79M396.55M228.21M270.31M278.51M240.98M213.99M
Cash55.00K97.00K22.09M2.18M16.66M2.30M24.96M36.71M71.35M462.89M370.49M391.88M292.00M237.03M230.91M
Total Debt-662.00K---133.00K-9.91M20.67M20.75M69.15M94.75M30.22M28.55M25.00M
Net Debt-55.00K565.00K-22.09M-2.18M-16.66M-2.17M-24.96M-26.80M-50.68M-442.14M-301.35M-297.13M-261.79M-208.48M-205.91M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.36M-1.58M-7.35M-28.33M-18.15M-19.24M-460.00K-20.76M-6.45M-42.86M-135.04M31.99M-18.10M-59.75M-74.27M
Investing Cash Flow-1.04M1.03M-28.05M8.41M-33.84M4.88M10.36M22.13M-818.00K-1.74M-3.41M-7.73M-2.90M-648.00K-230.00K
Financing Cash Flow2.62M601.00K57.40M66.47M66.47M6.00K7.00M10.20M41.91M436.14M48.02M-2.86M-24.09M5.42M13.38M
Capital Expenditure24.00K039.00K79.00K181.00K74.00K251.00K1.48M818.00K1.74M3.41M7.73M2.90M648.00K230.00K
Free Cash Flow-2.38M-1.58M-7.39M-28.41M-18.33M-19.32M-711.00K-22.24M-7.26M-44.60M-138.45M24.27M-21.00M-60.40M-74.27M
FCF to OCF101.02%100.00%100.53%100.28%101.00%100.38%154.57%107.12%112.69%104.06%102.52%75.85%116.03%101.08%100.00%

Earnings

Report DateAug 6, 2013Nov 7, 2013Feb 13, 2014May 15, 2014Aug 11, 2014Nov 17, 2014Feb 12, 2015May 6, 2015Aug 13, 2015Nov 12, 2015Feb 17, 2016May 16, 2016Aug 30, 2016Nov 15, 2016Feb 15, 2017May 30, 2017Aug 11, 2017Nov 9, 2017Feb 15, 2018May 14, 2018Sep 28, 2018Nov 7, 2018Mar 18, 2019May 13, 2019Aug 14, 2019Nov 8, 2019Mar 11, 2020May 7, 2020Aug 10, 2020Nov 9, 2020Mar 1, 2021May 10, 2021Aug 9, 2021Nov 8, 2021Feb 28, 2022May 9, 2022Aug 9, 2022Nov 9, 2022Mar 28, 2023May 9, 2023Aug 7, 2023Nov 14, 2023Mar 7, 2024May 8, 2024Aug 5, 2024Nov 7, 2024Mar 5, 2025May 12, 2025Aug 11, 2025Nov 10, 2025Mar 3, 2026May 8, 2026Aug 6, 2026Nov 9, 2026
EPS Estimate-0.42-0.63-2.20-2.85-3.71-3.89-4.20-2.01-2.01-2.17-1.68-1.51-1.53-1.80-1.90-1.26-0.94-2.66-0.46-0.46-0.70-0.35-0.48-0.60-0.61-0.46-0.51-0.61-0.55-0.49-0.88-1.23-2.25-1.52-1.72-1.40-1.88-1.810.980.26-0.42-1.63-0.99-1.14-1.57-1.02-0.49-1.10-0.85-0.80-0.76-1.01-1.07-0.60
EPS Actual-0.42-1.96-3.15-3.71-3.99-5.39-3.50-1.82-1.68-1.40-1.40-1.26-1.47-1.96-1.54-0.91-0.91-0.70-1.08-1.08-0.99-0.42-0.08-0.68-0.07-0.56-0.76-0.67-0.55-0.92-1.25-2.15-2.07-2.05-1.47-1.94-0.82-1.334.430.63-1.98-0.61-0.32-1.00-0.64-0.26-1.11-0.52-0.34-0.49-1.03-0.95-0.84-
Surprise0.00%-211.11%-43.18%-30.18%-7.55%-38.56%16.67%9.45%16.42%35.48%16.67%16.56%3.92%-8.89%18.95%27.78%3.19%73.68%-134.78%-134.78%-41.43%-20.00%83.33%-13.33%88.52%-21.74%-49.02%-9.84%0.00%-87.76%-42.05%-74.80%8.00%-34.87%14.53%-38.57%56.38%26.52%352.04%142.31%-371.43%62.58%67.68%12.28%59.24%74.51%-124.56%52.73%60.00%38.75%-35.53%6.25%21.50%-
Timing----Pre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap401.33M
Enterprise Value209.76M
Trailing P/E0.00
Forward P/E2.48
Price / Sales13.67
Price / Book2.20
EPS-3.33
Book Value6.05
Revenue (TTM)29.37M
Gross Profit (TTM)-57.41M
EBITDA-99.55M
Profit Margin0.00%
Operating Margin-863.30%
Return on Equity-46.31%
Return on Assets-23.96%
Shares Outstanding28.42M
Shares Float26.15M
Beta2.48
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 11 analystsTarget 23.20
  • Strong Buy
    8
  • Buy
    3

Ownership Breakdown

Institutions
83.19%
Insiders
7.99%
Retail / Other
8.82%

Top Institutional Holders

  • Federated Hermes Inc
    3.30M11.62%
  • ARK Investment Management LLC
    2.77M9.74%
  • BlackRock Inc
    2.61M9.19%
  • Sumitomo Mitsui Trust Group Inc
    1.96M6.91%
  • Amova Asset Management Americas, Inc
    1.96M6.90%
  • Vanguard Capital Management, LLC
    1.11M3.89%
  • Two Sigma Investments LLC
    1.09M3.84%
  • Vanguard Portfolio Management, LLC
    977.92K3.44%
  • Geode Capital Management, LLC
    660.93K2.33%
  • State Street Corp
    543.86K1.91%
  • UBS Group AG
    458.28K1.61%
  • D. E. Shaw & Co LP
    392.36K1.38%
  • Empire Life Investments Inc
    366.22K1.29%
  • Hennion & Walsh Asset Management Inc
    346.21K1.22%

Top Fund Holders

  • ARK Genomic Revolution ETF
    2.90M10.22%
  • Federated Hermes Kaufmann R
    2.07M7.29%
  • Amova ARK Pstv Chg Innovt P JPY Acc
    1.60M5.65%
  • Federated Hermes Kaufmann Small Cap A
    1.19M4.18%
  • Vanguard MStar Total Stk Mkt Idx Invest
    797.15K2.80%
  • iShares Russell 2000 ETF
    701.69K2.47%

Stock Splits

  • Nov 16, 20171:7